Why Your Resting Heart Rate Is Higher on a GLP-1

Across clinical trials, GLP-1 medications raise resting heart rate by roughly 1 to 4 beats per minute on average. Semaglutide trials cluster around a 2 to 3 bpm increase compared with placebo. A network meta-analysis of randomized trials in people with overweight or obesity but without diabetes found tirzepatide raised heart rate by about 2.05 bpm versus placebo, with the lowest dose (5 mg) producing the smallest change.

To put that in context: a 2 bpm increase on a baseline of 68 bpm moves you to 70 bpm. Most people would never detect that without a device. The reason it feels like a bigger deal now than it did a decade ago is that millions of people are wearing continuous heart rate monitors and watching a number that used to be checked twice a year at a physical.

The increase is also not evenly distributed. Trial averages hide a spread. A minority of participants saw increases of 10 bpm or more, and a similar minority saw their heart rate go *down*, usually the people who lost the most weight and improved their sleep apnea. If you are the person whose watch went from 62 to 78, you are not imagining it and you are not average.

One more distinction that matters: this is resting heart rate. GLP-1s do not appear to meaningfully change your maximum heart rate or your heart's response to exercise. If you track your workouts, you may notice your usual pace now sits in a slightly higher heart rate zone, which is one reason [VO2 max readings on a GLP-1 can mislead](/blog/vo2-max-on-glp1-during-menopause-why-the-number-misleads).

GLP-1 medications raise heart rate because GLP-1 receptors sit directly on the sinoatrial node — the cluster of cells in the right atrium that sets your heart's rhythm. When the drug binds there, those cells fire slightly faster. This is a direct pharmacological effect, not a stress response or a sign that your heart is straining.

There are at least three overlapping mechanisms researchers have identified:

Direct sinoatrial stimulation. GLP-1 receptor activation in the pacemaker tissue increases the rate of spontaneous depolarization. This is the dominant effect and it explains why the heart rate rise shows up within days of a dose increase rather than gradually over months.

Autonomic shift. GLP-1s appear to nudge the balance between your sympathetic ('fight or flight') and parasympathetic ('rest and digest') nervous systems slightly toward sympathetic. This is also why some people notice a modest drop in heart rate variability, or HRV, on a wearable.

Indirect effects from eating and drinking less. This one is underrated. When your appetite drops, your fluid intake often drops with it. Mild dehydration reduces blood volume, and your heart compensates by beating faster to maintain the same output. The same is true if you are eating far fewer calories than your body needs.

That third mechanism is the good news, because it is the one you can actually do something about. Before you assume the drug is the whole story, it is worth ruling out the fixable contributors — which is the next section.

For most people, no — and the trial evidence on this is unusually strong. The concern is reasonable in principle, because in the general population a higher resting heart rate is associated with worse cardiovascular outcomes over decades. But that association comes from people whose heart rate is elevated *because* something else is wrong: poor fitness, chronic inflammation, heart failure, untreated sleep apnea.

A drug-induced heart rate increase in an otherwise improving metabolic picture appears to behave differently. The SELECT trial (NEJM 2023) followed more than 17,000 adults with overweight or obesity and established cardiovascular disease for over three years. Semaglutide 2.4 mg reduced major adverse cardiovascular events — cardiovascular death, heart attack, and stroke — by 20% compared with placebo. That benefit occurred alongside the same small heart rate increase seen in every other semaglutide trial.

Similar reassurance comes from the diabetes trials. Large phase 3 programs comparing tirzepatide against other glucose-lowering drugs found the small heart rate rise but no increase in cardiovascular adverse events. You can read more in our breakdown of [what the SELECT trial changed](/blog/glp1-heart-health-select-trial-cardiovascular-benefits).

The honest caveat: these trials were not designed to study the subgroup of people whose heart rate jumped 15 bpm. If you are in that group, or you have a pre-existing arrhythmia, heart failure, or a history of tachycardia, the general reassurance is less applicable to you personally. That is a conversation for your cardiologist, not a blog post.

Before you attribute the whole increase to the medication, work through the list of things that commonly rise alongside it. In practice, a meaningful share of the 'GLP-1 tachycardia' people report on forums turns out to be one of these:

Dehydration. This is the most common and the most fixable. Appetite suppression reduces thirst cues and reduces the water you normally get from food. Even 2% dehydration measurably raises resting heart rate. If your urine is dark and your heart rate is up, start here — see our guide to [hydration and why you feel so thirsty](/blog/hydration-on-glp1-during-menopause-why-so-thirsty).

Low electrolytes. Potassium and magnesium keep cardiac cells electrically stable. If you have had vomiting or diarrhea, or you have cut your food volume dramatically, these can drop. Low magnesium in particular is linked to palpitations and a racing pulse.

Under-eating. Eating far below your needs triggers a stress hormone response. Cortisol and adrenaline both raise heart rate.

Iron deficiency anemia. Very common in perimenopausal women with heavy periods, and a classic cause of a resting heart rate that creeps into the 90s. GLP-1s can reduce iron absorption further by slowing gastric emptying and reducing red-meat intake.

Thyroid dysfunction. An overactive thyroid raises heart rate. It is also frequently mistaken for perimenopause.

Caffeine, alcohol, and poor sleep. Obvious, but worth auditing. Many people on a GLP-1 increase coffee to replace the energy of food.

Anxiety. Starting a new medication and watching a number on your wrist is itself a heart-rate-raising activity. This is a real effect, not a dismissal.

For most people, the pattern is a step up after each dose escalation followed by a plateau. You increase from 0.5 mg to 1.0 mg, your resting heart rate rises 1 to 2 bpm over the following week or two, and then it stabilizes at the new level. It does not keep climbing indefinitely.

What happens over the longer term is more interesting. Two forces pull in opposite directions. The drug effect pushes heart rate up. Meanwhile, weight loss, improved sleep apnea, better blood pressure, and improved insulin sensitivity all push resting heart rate down. In people who lose a substantial amount of weight and had untreated sleep apnea, the second force often wins by month six or nine, and their resting heart rate ends up lower than where it started.

If you stop the medication, the drug-driven portion of the increase resolves within a few weeks as the medication clears — semaglutide has a half-life of about a week, so figure four to five weeks for full washout.

A practical note for anyone tracking this on a wearable: measure at the same time under the same conditions. First thing in the morning, before you get out of bed, before caffeine. Comparing a Tuesday afternoon reading to a Sunday morning reading will produce noise far larger than the 2 bpm signal you are trying to detect. Our guide to [reading heart rate and HRV data on a GLP-1](/blog/wearables-on-glp1-during-menopause-heart-rate-hrv-explained) goes deeper on this.

Most heart rate changes on a GLP-1 need monitoring, not intervention. These specific situations need a phone call:

A resting heart rate consistently above 100 bpm. That is the clinical threshold for tachycardia. One anxious reading does not count; a pattern over several mornings does.

An increase of more than 10 to 15 bpm from your baseline. This is outside the expected range and deserves a workup for the contributors listed above.

Heart rate elevation with any of these symptoms: chest pain or pressure, fainting or near-fainting, shortness of breath at rest, or a heartbeat that feels irregular rather than just fast. An irregular rhythm is a different problem from a fast one and needs an ECG.

Palpitations that wake you at night. Especially relevant in perimenopause, where hormonal palpitations and medication effects can stack. Our article on [heart palpitations in menopause](/blog/menopause-heart-palpitations-why-your-heart-races-and-what-helps) covers how to tell them apart.

Any heart rate change if you have a known arrhythmia, heart failure, or valve disease. The general reassurance from trials in healthier populations does not automatically transfer.

What your doctor will likely do: check a resting ECG, run a basic metabolic panel with magnesium, check a complete blood count for anemia, and check thyroid function. If everything is normal and the rate is mildly elevated, the usual recommendation is to continue the medication and recheck. Lowering the dose is an option but is rarely the first move, because the cardiovascular benefit of staying on treatment generally outweighs a few extra beats per minute.

Do not stop a GLP-1 on your own because of a wearable reading. Bring the data, ask the question, decide together.